Retevmo (selpercatinib) is a brand-name drug prescribed for certain types of cancer in adults and some children. Retevmo comes as an oral capsule that’s typically taken twice per day, but the dosage ...

Progression-free survival improved with Retevmo as the initial treatment for patients with advanced RET-mutant medullary thyroid cancer. Retevmo (selpercatinib) improved progression-free survival ...

If you have a certain thyroid or lung cancer, your doctor may prescribe Retevmo for you. It’s a prescription drug that’s used to treat the following cancers in specific situations: With advanced ...

Retevmo is an U.S. FDA-approved oral prescription medicine, 120 mg or 160 mg dependent on weight (<50 kg or ≥50 kg, respectively), taken twice daily until disease progression or unacceptable toxicity.

Retevmo as a treatment for patients with advanced RET-mutant medullary thyroid cancer “is very exciting,” as treatment options were previously limited, an expert told CURE®. Treatment with Retevmo ...

Add Yahoo as a preferred source to see more of our stories on Google. Eli Lilly will speak with regulators about the Phase III data. Image credit: luchschenF / Shutterstock.com (luchschenF / ...

Selpercatinib demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or death Results from the LIBRETTO-432 trial build on ...

Some six years after the FDA approved Eli Lilly’s Retevmo to treat lung and thyroid cancers that have a mutation or fusion to the RET gene, the Indianapolis drugmaker is laying groundwork to move the ...

Median progression free survival in the selpercatinib group was not reached and was 16.8 months in the cabozantinib/vandetanib group. The Food and Drug Administration ...

--Eli Lilly and Company today announced topline results from the LIBRETTO-531 study evaluating Retevmo versus physician's choice of the multikinase inhibitors cabozantinib or vandetanib as an initial ...

Results from LIBRETTO-121 showed a confirmed overall response rate of 48% (95% CI, 28-69). The Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the ...

INDIANAPOLIS, Aug. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced topline results from the LIBRETTO-431 study evaluating Retevmo versus platinum-based chemotherapy plus pemetrexed ...